[시장보고서]미국의 호르몬 요법(소매 부문) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 투여 경로별, 유통 채널별, 부문별 예측(2025-2033년)

미국의 호르몬 요법(소매 부문) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 투여 경로별, 유통 채널별, 부문별 예측(2025-2033년)

U.S. Hormone Therapy (Retail Side) Market Size, Share & Trends Analysis Report By Product (Sex Hormones, Thyroid Hormones), By Indication, By Route of Administration (Oral, Parenteral), By Distribution Channel, And Segment Forecasts, 2025 - 2033

상품코드 : 1813825

리서치사 : Grand View Research

발행일 : 2025년 08월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,950

￦ 5,733,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 4,950

￦ 7,184,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 6,950

￦ 10,087,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

시장 규모와 동향 :

미국의 호르몬 요법(소매 부문) 시장 규모는 2024년 116억 3,000만 달러로 평가되었습니다. 2033년에는 192억 2,000만 달러에 달하고, 2025-2033년 5.83%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

이 성장의 원동력은 고령화 인구 증가와 호르몬 장애 유병률 증가입니다. 또한, 경구용 알약, 경피용 패치, 피하 펠렛, 주사제 등 전달 기술의 발전으로 유효성, 편의성, 순응도가 향상되고 있습니다.

또한, 약국은 편리한 조제 및 상담을 제공하게 되었고, Ro, Noom, Midi Health와 같은 플랫폼은 원격 의료, 온라인 처방, 호르몬제 가정 배송, GLP-1 체중 감량 치료를 결합하여 매출을 증가시키고 있습니다.

시장 계통 전망
- 상위 시장 전망
- 관련/보조 시장 전망
시장 동향과 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
규제 프레임워크
비즈니스 환경 분석 툴
- 업계 분석 - Porter의 Five Forces 분석
- PESTEL 분석
온라인과 오프라인 채널 가격 분석
호르몬 요법에 관한 소비자 의식 동향
소비자 직접 판매(DTC) 비즈니스 모델 영향

제4장 제품 비즈니스 분석

미국의 호르몬 요법(소매 부문) 시장 : 제품 변동 분석
미국의 호르몬 요법(소매 부문) 시장 : 제품 부문 대시보드
제품 동향과 시장 점유율 분석, 2024년과 2033년
제품별
성호르몬
- 성호르몬 시장, 2021년-2033년
- 에스트로겐 보충 요법(ERT)
- 테스토스테론 보충 요법(TRT)
- 프로게스테론 요법
- 복합 호르몬 요법
갑상선 호르몬
성장 호르몬
부신 호르몬
기타 호르몬

제5장 적응증 비즈니스 분석

미국의 호르몬 요법(소매 부문) 시장 : 적응증 변동 분석
미국의 호르몬 요법(소매 부문) 시장 : 적응증 부문 대시보드
적응증 동향과 시장 점유율 분석, 2024년과 2033년
적응증별
갱년기 장애 및 남성 갱년기 장애 관리
갑상선 기능 저하증
성선 기능 저하증
성장호르몬 결핍증
성별 확인 치료
불임 치료
미용 용도
기타 적응증

제6장 투여 경로 비즈니스 분석

미국의 호르몬 요법(소매 부문) 시장 : 투여 경로 변동 분석
미국의 호르몬 요법(소매 부문) 시장 : 투여 경로 부문 대시보드
투여 경로 동향과 시장 점유율 분석, 2024년과 2033년
투여 경로별
경구
비경구
경피
기타 투여 경로

제7장 유통 채널 비즈니스 분석

미국의 호르몬 요법(소매 부문) 시장 : 유통 채널 변동 분석
미국의 호르몬 요법(소매 부문) 시장 : 유통 채널 부문 대시보드
유통 채널 동향과 시장 점유율 분석, 2024년과 2033년
유통 채널별
오프라인 약국
- 대형 체인점
- 독립계 약국
온라인 약국 및 원격의료
- 순수 온라인 약국
- 독립계 약국
원격의료와 구독 기반 DTC 브랜드

제8장 경쟁 구도

기업 분류(오프라인 약국)
기업 분류(온라인 약국)
기업 분류(호르몬 전문 클리닉)
참여 기업 개요
- Offline Pharmacies
- Online Pharmacies
- Specialized Hormone Clinics
기업 시장 현황 분석
전략 매핑
- 지역 확대
- 인수합병(M&A)
- 기타
기업 개요/상장기업
Offline Pharmacies
- CVS Health
- Walgreens Boots Alliance, Inc.
- Walmart Pharmacy
- Rite Aid Corp
- The Kroger Co.
- Albertsons
- Publix
- Costco Wholesale Corporation
- Meijer, Inc.
Online Pharmacies
- Hims &Hers Health, Inc
- CVS Health
- Ro(Roman Health Ventures Inc.)
- Lemonaid Health, Inc.
- Mark Cuban Cost Plus Drug Company, PBC
- Amazon.com, Inc.
- Blink Health Administration LLC, Inc.
- GoodRx, Inc
- Honeybee Health Inc.
- TruePill
- NURX Inc.
- AgelessRx
Specialized Hormone Clinics
- Hims &Hers Health, Inc
- BodyLogicMD
- Defy Medical
- Renew Vitality
- Victory Men's Health
- Hone Health
- Joi & Blokes
- Ways2Well
- Honeybee Health Inc.
- 4Ever Young Anti-aging Solutions
- T CLINICS USA

LSH

영문 목차

영문목차

Market Size & Trends:

The U.S. hormone therapy (retail side) market size was estimated at USD 11.63 billion in 2024 and is projected to reach USD 19.22 billion by 2033, growing at a CAGR of 5.83% from 2025 to 2033. This growth is driven by an increasing aging population and rising hormonal disorder prevalence. In addition, advances in delivery technologies, including oral pills, transdermal patches, subcutaneous pellets, and injectables, have enhanced efficacy, convenience, and adherence.

Moreover, the pharmacies now offer convenient dispensing and counseling, and platforms such as Ro, Noom, and Midi Health bundle telemedicine, online prescribing, and at-home delivery of hormones, with some combining GLP-1 weight-loss treatments, driving sales upward.

U.S. Hormone Therapy (Retail Side) Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. hormone therapy (retail side) market report based on product, indication, route of administration, and distribution channel:

Product Outlook (Revenue, USD Billion, 2021 - 2033)
Sex Hormones
- Estrogen Replacement Therapy (ERT)
- Testosterone Replacement Therapy (TRT)
- Progesterone Therapy
- Combined Hormone Therapy
Thyroid Hormones
Growth Hormones
Adrenal Hormones
Other Hormones
Indication Outlook (Revenue, USD Billion, 2021 - 2033)
Menopause & Andropause Management
Hypothyroidism
Hypogonadism
Growth Hormone Deficiency
Gender Affirming Therapy
Fertility Treatment
Cosmetic Applications
Other Indications
Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
Oral
Parenteral
Transdermal
Other Route of Administration
Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
Offline Retail Pharmacies
- Large chains
- Independent pharmacies
Online Pharmacies / Telehealth
- Pure-play online pharmacies
- Telehealth & subscription-based DTC brands
Others (Specialized Hormone Clinics)

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Segment Definitions
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.5. Details of Primary Research
- 1.4.6. Research Assumption
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
1.8. Objectives
- 1.8.1. Objective - 1
- 1.8.2. Objective - 2
- 1.8.3. Objective - 3
1.9. List of Secondary Sources
1.10. List of Secondary Sources

Chapter 2. Executive Summary

2.1. U.S. Hormone Therapy (Retail Side) Market
- 2.1.1. Market Snapshot
- 2.1.2. Segment Snapshot
  - 2.1.2.1. Product & indication segment outlook
  - 2.1.2.2. Route of administration & distribution channel segment outlook
- 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
3.4. Regulatory Framework
3.5. Business Environment Analysis Tools
- 3.5.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.5.1.1. Supplier power
  - 3.5.1.2. Buyer power
  - 3.5.1.3. Substitution threat
  - 3.5.1.4. Threat of new entrants
  - 3.5.1.5. Competitive rivalry
- 3.5.2. PESTEL Analysis
3.6. Pricing Analysis in Online vs. Offline Channels
3.7. Consumer Awareness Trends for Hormone Therapy
3.8. Direct-to-Consumer (DTC) Business Models Impact

Chapter 4. Product Business Analysis

4.1. U.S. Hormone Therapy (Retail Side) Market: Product Movement Analysis
4.2. U.S. Hormone Therapy (Retail Side) Market: Product Segment Dashboard
4.3. Product Movement & Market Share Analysis, 2024 & 2033
4.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Product
4.5. Sex Hormones
- 4.5.1. Sex Hormones Market, 2021 - 2033 (USD Million)
- 4.5.2. Estrogen Replacement Therapy (ERT)
  - 4.5.2.1. Estrogen Replacement Therapy (ERT) market, 2021 - 2033 (USD Million)
- 4.5.3. Testosterone Replacement Therapy (TRT)
  - 4.5.3.1. Testosterone Replacement Therapy (TRT) market, 2021 - 2033 (USD Million)
- 4.5.4. Progesterone Therapy
  - 4.5.4.1. Progesterone therapy market, 2021 - 2033 (USD Million)
- 4.5.5. Combined Hormone Therapy
  - 4.5.5.1. Combined hormone therapy market, 2021 - 2033 (USD Million)
4.6. Thyroid Hormones
- 4.6.1. Thyroid Hormones Market, 2021 - 2033 (USD Million)
4.7. Growth Hormones
- 4.7.1. Growth Hormones Market, 2021 - 2033 (USD Million)
4.8. Adrenal Hormones
- 4.8.1. Adrenal Hormones Market, 2021 - 2033 (USD Million)
4.9. Other Hormones
- 4.9.1. Other Hormones Market, 2021 - 2033 (USD Million)

Chapter 5. Indication Business Analysis

5.1. U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis
5.2. U.S. Hormone Therapy (Retail Side) Market: Indication Segment Dashboard
5.3. Indication Movement & Market Share Analysis, 2024 & 2033
5.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Indication
5.5. Menopause & Andropause Management
- 5.5.1. Menopause & Andropause Management Market, 2021 - 2033 (USD Million)
5.6. Hypothyroidism
- 5.6.1. Hypothyroidism Market, 2021 - 2033 (USD Million)
5.7. Hypogonadism
- 5.7.1. Hypogonadism Market, 2021 - 2033 (USD Million)
5.8. Growth Hormone Deficiency
- 5.8.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
5.9. Gender Affirming Therapy
- 5.9.1. Gender Affirming Therapy Market, 2021 - 2033 (USD Million)
5.10. Fertility Treatment
- 5.10.1. Fertility Treatment Market, 2021 - 2033 (USD Million)
5.11. Cosmetic Applications
- 5.11.1. Cosmetic Applications Market, 2021 - 2033 (USD Million)
5.12. Other Indications
- 5.12.1. Other Indications Market, 2021 - 2033 (USD Million)

Chapter 6. Route of Administration Business Analysis

6.1. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis
6.2. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Segment Dashboard
6.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
6.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Route of Administration
6.5. Oral
- 6.5.1. Oral Market, 2021 - 2033 (USD Million)
6.6. Parenteral
- 6.6.1. Parenteral Market, 2021 - 2033 (USD Million)
6.7. Transdermal
- 6.7.1. Transdermal Market, 2021 - 2033 (USD Million)
6.8. Other Route of Administration
- 6.8.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

Chapter 7. Distribution Channel Business Analysis

7.1. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis
7.2. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Segment Dashboard
7.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
7.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Distribution Channel
7.5. Offline Retail Pharmacies
- 7.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 7.5.2. Large Chains
  - 7.5.2.1. Large chains market, 2021 - 2033 (USD Million)
- 7.5.3. Independent Pharmacies
  - 7.5.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
7.6. Online Pharmacies / Telehealth
- 7.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
- 7.6.2. Pure-Play Online Pharmacies
  - 7.6.2.1. Pure-play online pharmacies market, 2021 - 2033 (USD Million)
- 7.6.3. Independent Pharmacies
  - 7.6.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
7.7. Telehealth & subscription-based DTC brands
- 7.7.1. Telehealth & subscription-based DTC brands Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization (Offline Pharmacies)
8.2. Company Categorization (Online Pharmacies)
8.3. Company Categorization (Specialized Hormone Clinics)
8.4. Participant's Overview
- 8.4.1. Offline Pharmacies
- 8.4.2. Online Pharmacies
- 8.4.3. Specialized Hormone Clinics
8.5. Company Market Position Analysis
8.6. Strategy Mapping
- 8.6.1. Regional Expansion
- 8.6.2. Mergers & Acquisitions
- 8.6.3. Others
8.7. Company Profiles/Listing
8.8. Offline Pharmacies
- 8.8.1. CVS Health
  - 8.8.1.1. Overview
  - 8.8.1.2. Financial performance
  - 8.8.1.3. Product benchmarking
  - 8.8.1.4. Strategic initiatives
- 8.8.2. Walgreens Boots Alliance, Inc.
  - 8.8.2.1. Overview
  - 8.8.2.2. Financial performance
  - 8.8.2.3. Product benchmarking
  - 8.8.2.4. Strategic initiatives
- 8.8.3. Walmart Pharmacy
  - 8.8.3.1. Overview
  - 8.8.3.2. Financial performance
  - 8.8.3.3. Product benchmarking
  - 8.8.3.4. Strategic initiatives
- 8.8.4. Rite Aid Corp
  - 8.8.4.1. Overview
  - 8.8.4.2. Financial performance
  - 8.8.4.3. Product benchmarking
  - 8.8.4.4. Strategic initiatives
- 8.8.5. The Kroger Co.
  - 8.8.5.1. Overview
  - 8.8.5.2. Financial performance
  - 8.8.5.3. Product benchmarking
  - 8.8.5.4. Strategic initiatives
- 8.8.6. Albertsons
  - 8.8.6.1. Overview
  - 8.8.6.2. Financial performance
  - 8.8.6.3. Product benchmarking
  - 8.8.6.4. Strategic initiatives
- 8.8.7. Publix
  - 8.8.7.1. Overview
  - 8.8.7.2. Financial performance
  - 8.8.7.3. Product benchmarking
  - 8.8.7.4. Strategic initiatives
- 8.8.8. Costco Wholesale Corporation
  - 8.8.8.1. Overview
  - 8.8.8.2. Financial performance
  - 8.8.8.3. Product benchmarking
  - 8.8.8.4. Strategic initiatives
- 8.8.9. Meijer, Inc.
  - 8.8.9.1. Overview
  - 8.8.9.2. Financial performance
  - 8.8.9.3. Product benchmarking
  - 8.8.9.4. Strategic initiatives
8.9. Online Pharmacies
8.10. Hims & Hers Health, Inc
- 8.10.1. CVS Health
  - 8.10.1.1. Overview
  - 8.10.1.2. Financial performance
  - 8.10.1.3. Product benchmarking
  - 8.10.1.4. Strategic initiatives
- 8.10.2. Ro (Roman Health Ventures Inc.)
  - 8.10.2.1. Overview
  - 8.10.2.2. Financial performance
  - 8.10.2.3. Product benchmarking
  - 8.10.2.4. Strategic initiatives
- 8.10.3. Lemonaid Health, Inc.
  - 8.10.3.1. Overview
  - 8.10.3.2. Financial performance
  - 8.10.3.3. Product benchmarking
  - 8.10.3.4. Strategic initiatives
- 8.10.4. Mark Cuban Cost Plus Drug Company, PBC
  - 8.10.4.1. Overview
  - 8.10.4.2. Financial performance
  - 8.10.4.3. Product benchmarking
  - 8.10.4.4. Strategic initiatives
- 8.10.5. Amazon.com, Inc.
  - 8.10.5.1. Overview
  - 8.10.5.2. Financial performance
  - 8.10.5.3. Product benchmarking
  - 8.10.5.4. Strategic initiatives
- 8.10.6. Blink Health Administration LLC, Inc.
  - 8.10.6.1. Overview
  - 8.10.6.2. Financial performance
  - 8.10.6.3. Product benchmarking
  - 8.10.6.4. Strategic initiatives
- 8.10.7. GoodRx, Inc
  - 8.10.7.1. Overview
  - 8.10.7.2. Financial performance
  - 8.10.7.3. Product benchmarking
  - 8.10.7.4. Strategic initiatives
- 8.10.8. Honeybee Health Inc.
  - 8.10.8.1. Overview
  - 8.10.8.2. Financial performance
  - 8.10.8.3. Product benchmarking
  - 8.10.8.4. Strategic initiatives
- 8.10.9. TruePill
  - 8.10.9.1. Overview
  - 8.10.9.2. Financial performance
  - 8.10.9.3. Product benchmarking
  - 8.10.9.4. Strategic initiatives
- 8.10.10. NURX Inc.
  - 8.10.10.1. Overview
  - 8.10.10.2. Financial performance
  - 8.10.10.3. Product benchmarking
  - 8.10.10.4. Strategic initiatives
- 8.10.11. AgelessRx
  - 8.10.11.1. Overview
  - 8.10.11.2. Financial performance
  - 8.10.11.3. Product benchmarking
  - 8.10.11.4. Strategic initiatives
8.11. Specialized Hormone Clinics
8.12. Hims & Hers Health, Inc
- 8.12.1. BodyLogicMD
  - 8.12.1.1. Overview
  - 8.12.1.2. Financial performance
  - 8.12.1.3. Product benchmarking
  - 8.12.1.4. Strategic initiatives
- 8.12.2. Defy Medical
  - 8.12.2.1. Overview
  - 8.12.2.2. Financial performance
  - 8.12.2.3. Product benchmarking
  - 8.12.2.4. Strategic initiatives
- 8.12.3. Renew Vitality
  - 8.12.3.1. Overview
  - 8.12.3.2. Financial performance
  - 8.12.3.3. Product benchmarking
  - 8.12.3.4. Strategic initiatives
- 8.12.4. Victory Men's Health
  - 8.12.4.1. Overview
  - 8.12.4.2. Financial performance
  - 8.12.4.3. Product benchmarking
  - 8.12.4.4. Strategic initiatives
- 8.12.5. Hone Health
  - 8.12.5.1. Overview
  - 8.12.5.2. Financial performance
  - 8.12.5.3. Product benchmarking
  - 8.12.5.4. Strategic initiatives
- 8.12.6. Joi & Blokes
  - 8.12.6.1. Overview
  - 8.12.6.2. Financial performance
  - 8.12.6.3. Product benchmarking
  - 8.12.6.4. Strategic initiatives
- 8.12.7. Ways2Well
  - 8.12.7.1. Overview
  - 8.12.7.2. Financial performance
  - 8.12.7.3. Product benchmarking
  - 8.12.7.4. Strategic initiatives
- 8.12.8. Honeybee Health Inc.
  - 8.12.8.1. Overview
  - 8.12.8.2. Financial performance
  - 8.12.8.3. Product benchmarking
  - 8.12.8.4. Strategic initiatives
- 8.12.9. 4Ever Young Anti-aging Solutions
  - 8.12.9.1. Overview
  - 8.12.9.2. Financial performance
  - 8.12.9.3. Product benchmarking
  - 8.12.9.4. Strategic initiatives
- 8.12.10. T CLINICS USA
  - 8.12.10.1. Overview
  - 8.12.10.2. Financial performance
  - 8.12.10.3. Product benchmarking
  - 8.12.10.4. Strategic initiatives